Agilent Technologies (A - Free Report) is set to report fiscal second-quarter 2019 results on May 14. In the last reported quarter, the company delivered a positive earnings surprise of 4.11%.
Agilent’s surprise history has been pretty impressive. It beat estimates in three of the trailing four quarters, with average positive earnings surprise of 5.36%.
Let’s see how things are shaping up for this announcement.
Strength in ACG Segment to Drive Revenues
The company generated strong revenues from this segment in the last reported quarter.
The revenue figure is expected to further increase in the to-be-reported quarter, driven by strength in services and consumables across all geographical regions served. The Zacks Consensus Estimate for this segment is currently pegged at 446 million.
Strength in DGG & LSAG
The company expects strong revenues from Diagnostics and Genomics Group (DGG) in the to-be-reported quarter, driven by growth in pharma, along with strength in genomics and NASD products.
Also, the Life Sciences & Applied Markets Group (LSAG) segment is likely to report solid numbers in the quarter to be reported, driven by strong performances in chemical and energy, as well as pharma and environmental markets.
The Zacks Consensus Estimate for DGG & LSAG is currently pegged at 252 million and 568 million, respectively.
Other Growth Drivers
Agilent’s broad-based portfolio and increased focus on segments offer higher growth potential. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base, and the diversification of geographic and industrial growth operations.
Also, the company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is a positive.
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Zacks Rank #4 or 5 (Sell rated) stocks are best avoided, especially if these have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent currently has a Zacks Rank#2 and an Earnings ESP of 0.00%, a combination that does not indicate a likely positive surprise in the to-be-reported quarter.
Stocks to Consider
We see a likely earnings beat for each of the following companiesin the upcoming releases:
Target Corporation (TGT - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank #2.
Intuit Inc. (INTU - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Netflix, Inc. (NFLX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Agilent Technologies (A - Free Report) is set to report fiscal second-quarter 2019 results on May 14. In the last reported quarter, the company delivered a positive earnings surprise of 4.11%.
Agilent’s surprise history has been pretty impressive. It beat estimates in three of the trailing four quarters, with average positive earnings surprise of 5.36%.
Let’s see how things are shaping up for this announcement.
Strength in ACG Segment to Drive Revenues
The company generated strong revenues from this segment in the last reported quarter.
The revenue figure is expected to further increase in the to-be-reported quarter, driven by strength in services and consumables across all geographical regions served. The Zacks Consensus Estimate for this segment is currently pegged at 446 million.
Strength in DGG & LSAG
The company expects strong revenues from Diagnostics and Genomics Group (DGG) in the to-be-reported quarter, driven by growth in pharma, along with strength in genomics and NASD products.
Also, the Life Sciences & Applied Markets Group (LSAG) segment is likely to report solid numbers in the quarter to be reported, driven by strong performances in chemical and energy, as well as pharma and environmental markets.
The Zacks Consensus Estimate for DGG & LSAG is currently pegged at 252 million and 568 million, respectively.
Other Growth Drivers
Agilent’s broad-based portfolio and increased focus on segments offer higher growth potential. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base, and the diversification of geographic and industrial growth operations.
Also, the company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is a positive.
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Zacks Rank #4 or 5 (Sell rated) stocks are best avoided, especially if these have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent currently has a Zacks Rank#2 and an Earnings ESP of 0.00%, a combination that does not indicate a likely positive surprise in the to-be-reported quarter.
Stocks to Consider
We see a likely earnings beat for each of the following companiesin the upcoming releases:
Target Corporation (TGT - Free Report) has an Earnings ESP of +0.42% and a Zacks Rank #2.
Intuit Inc. (INTU - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Netflix, Inc. (NFLX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NFLX - FREE
Get the latest research report on TGT - FREE
Get the latest research report on A - FREE
Get the latest research report on INTU - FREE